A Study of KL590586 in Patients With Advanced Solid Tumors

NCT05265091 | Active Not Recruiting Phase 1

• 1 other identifier: KL400-Ⅰ/Ⅱ-01
• Study Type: interventional
• Target: 414
• Locations: 1 country
• Sites: 1

Brief Summary

An Open, Multi-Center Phase I/II Clinical Study To Evaluate The Safety, Tolerability, Pharmacokinetic Characteristics And Effectiveness Of KL590586 Capsules In Patients With Advanced Solid Tumors Carrying RET Fusion Or Mutant Genes

Conditions

Advanced Solid Tumor

Keywords

Lung; NSCLC; Thyroid

Outcome Measures

Primary Outcomes (2)

• Phase I: Dose limiting toxicities (DLT)

  Incidence rate of dose limiting toxicities (DLT)

  From date of initial dose until up to 28 days for treatment

• Phase II: ORR

  Objective response rate (ORR)

  Approximately 12 months

Study Arms (1)

KL590586

EXPERIMENTAL

Multiple doses of KL590586 capsule

Drug: KL590586 Capsule

Interventions

KL590586 Capsule DRUG

Product Name: KL590586 Capsules Formulation：Capsule Specification: 10mg; 50mg Ingredients: KL590586, microcrystalline cellulose, mannitol, cross-linked sodium carboxymethylcellulose, colloidal silicon dioxide, magnesium stearate, hydroxypropylmethylcellulose hollow capsule

KL590586

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Stage I: locally advanced or metastatic solid tumors that are pathologically diagnosed without standard treatment or intolerant to standard treatments
• Stage II: locally advanced or metastatic NSCLC, MTC or other solid tumors confirmed by pathology
• There is at least one measurable target lesion that meets RECIST v1.1 or RANO (only for brain tumor lesions)
• Age \> or = 18 years old at the time of signing the informed consent form, regardless of gender
• Within 14 days before the first administration of the study treatment, the Eastern Cooperative Oncology Group (ECOG) performance status score was 0 or 1, and there was no sudden deterioration, and the expected survival time was \> or = 3 months
• Sufficient organ and bone marrow function (without receiving blood transfusion, erythropoietin, recombinant human thrombopoietin or colony stimulating factor therapy, renal replacement therapy, etc. within 7 days before the examination, the laboratory examination meets the following conditions Regulations): a) Blood routine: absolute neutrophil count (ANC) \> or = 1.0×10\^9/L; platelet count (PLT) \> or = 75×10\^9/L; hemoglobin concentration \> or = 9.0 g/dl; b) Liver function: AST and ALT \< or = 2.5×upper limit of normal (ULN), TBIL\< or = 1.5×ULN; for patients with liver metastasis or primary biliary tract tumors, ALT and AST \< or = 5×ULN; for liver cancer, liver metastasis or Gil Patients with Gilbert's syndrome, TBIL \< or = 3×ULN; c) Renal function: serum creatinine (Cr) \< or = 1.5×ULN or creatinine clearance \> or = 40 ml/min (using the standard Cockcroft-Gault formula); d) Coagulation function: International normalized ratio (INR), activated partial thromboplastin time (APTT) and prothrombin time (PT) \< or = 1.5×ULN;
• Able to understand and voluntarily sign an informed consent form, and be able to comply with the visit and related procedures stipulated in the plan

You may not qualify if:

• There are known major driver gene changes other than RET. For example, NSCLC carrying targeted mutations such as EGFR, ALK, ROS1 or BRAF; colorectal cancer carrying mutations such as oncogenic KRAS, NRAS or BRAF. If the patient has a co-mutation, the investigator should discuss with the sponsor whether the patient can be included in the group
• Symptomatic primary central nervous system (CNS) tumors, brain metastases, leptomeningeal carcinogenesis, or untreated spinal cord compression that the researchers believe require local intervention
• People with other active malignant tumors (except for non-melanoma skin cancer in situ, cervical cancer in situ and other localized tumors that have been cured and have not recurred within 5 years)
• Need to use drugs known to be potent inhibitors or inducers of CYP3A4, drugs known to prolong QTc, and the treatment cannot be terminated at least 14 days before the study drug is administered
• Received the following anti-tumor treatments: a) The previous anti-tumor drug treatment (except immunotherapy or other antibody therapy) is less than 14 days or 5 half-lives (whichever is longer) from the first treatment with study drug; b) In Those who have received any immunotherapy or other antibody treatment within 28 days before the first study drug administration; c) Those who have received more than 30% of bone marrow radiation or wide-range radiotherapy within 28 days before the first study drug treatment (the patients receiving palliative radiotherapy are the first Within 7 days before receiving study drug treatment)
• Received major surgical operations within 28 days before receiving the first study drug treatment (excluding operations such as central venous catheter placement, tumor biopsy, and gastric tube placement)
• Those who have received other clinical trial drug treatment within 28 days before receiving the first study drug treatment
• Any original symptoms that may interfere with the results of the study, including: any unrecovered toxicity above grade 1 of the CTCAE related to previous anti-tumor therapy (hair loss and grade 2 neuropathy related to previous platinum-based drug treatment, etc.) Except for chronic toxicity judged by the person
• Patients with clinically active interstitial lung disease, active pneumonia, and radiation pneumonia requiring treatment, or those who have been found or suspected of having such diseases during the screening period
• Poorly controlled pleural effusion, abdominal effusion, or pericardial effusion after intervention (such as drainage)
• Any serious and/or uncontrolled comorbidities that may prevent the patient from participating in the study
• Those who are known to be allergic to any component in the study drug prescription
• Clinically significant active malabsorption syndrome or other diseases that may affect study drug administration and gastrointestinal absorption
• Active hepatitis B (hepatitis B surface antigen is positive and HBV-DNA is higher than the upper limit of normal detection) or hepatitis C (hepatitis C antibody is positive and HCV-RNA is higher than the upper limit of normal detection); Human immunodeficiency virus (HIV) examination Positive or known acquired immunodeficiency syndrome (AIDS); Treponema pallidum antibody test is positive
• Pregnant or breastfeeding women, fertility patients (regardless of male and female) who cannot take effective medical contraceptive measures during the study period and within 6 months after the last administration

Sponsors & Collaborators

• Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.: lead

Study Sites (1)

Sichuan Kelun Botai Biopharmaceutical Co.

Chengdu, Sichuan, 610000, China

Location

MeSH Terms

Conditions

Thyroid Diseases

Condition Hierarchy (Ancestors)

Endocrine System Diseases

Study Officials

• Xiangqian Zheng, Professor

  Tianjin Medical University Cancer Institute and Hospital

  PRINCIPAL INVESTIGATOR

• Shanghua Jing, Professor

  The Fourth Hospital of Hebei Medical University and Hebei Cancer Hospital

  PRINCIPAL INVESTIGATOR

• Anwen Liu, Professor

  Second Affiliated Hospital of Nanchang University

  PRINCIPAL INVESTIGATOR

• Yilong Wu, Professor

  Guangdong Provincial People's Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 14, 2022
• First Posted: March 3, 2022
• Study Start: September 15, 2021
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): December 31, 2026
• Last Updated: December 18, 2025

Record last verified: 2025-12

Locations

CN (1)